



02041604


P.E 6-3-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN ISSUER

**PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**



For the month of June 2002

Hemosol Inc.

(Translation of registrant's name into English)

2585 Meadowpine Boulevard, Mississauga, Ontario, L5N 8H9, Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒

PROCESSED

JUL 01 2002

**THOMSON
FINANCIAL**

P

The following is included in this Report on Form 6-K:

1. Press Release, dated June 20, 2002



HEMOSOL INC.

Investor Center

Viewing: News Headlines

Hemosol Receives Key U.S. Patent Approval

TORONTO, ON, June 20, 2002 – Hemosol Inc. (NASDAQ: HMSL, TSX: HML, HML.WT) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for the Company's patent application entitled "Hemoglobin-Haptoglobin Complexes". The U.S. patent is the first to be allowed for this invention with several additional applications pending in other countries including Canada. The "Hemoglobin-Haptoglobin Complexes" patent family covers products and methods for the targeted delivery of drugs and bioactive molecules via hemoglobin-haptoglobin complexes that are being developed under the HepSelectä platform.

"This patent will strengthen Hemosol's portfolio of drug delivery patents and will play a key role in our strategy to accelerate the commercial development of Hemosol's pipeline products and maintain valuable competitive advantages," said Dr. David Bell, Vice President of Drug Development at Hemosol. "To enhance our progress we are actively pursuing financial partnerships that will provide the resources necessary to bring these exciting new product candidates to market." The hemoglobin-based drug delivery patent portfolio also includes patents covering the attachment of drugs and imaging agents to hemoglobin ("Hemoglobins as Drug Delivery Agents"). The Company regards its strong Intellectual Property position as a key element in its ultimate commercial success by providing market exclusivity for 20 years after filing. The HepSelectä platform technology is designed to allow therapeutic drugs to be concentrated in receptor-bearing cells while protecting other cells from drug toxicity. The HepSelectä platform should enable a wide variety of drugs that are otherwise unstable, rapidly cleared or unsuitable for systemic administration to be used to treat viral diseases and cancers of the liver.

Hemosol is actively developing a rich pipeline of platform technologies and new product candidates. The Company's Protein Bioconjugation program includes a hemoglobin-based oxygen therapeutic with potential application in high volume blood loss situations (HRC 101), an oxygen therapeutic (HRC 102) designed to prevent oxidative damage during tissue reperfusion and the HepSelectä drug delivery platform with potential use for treatment of liver diseases (HRC 203 and HRC 204). In the Cell Expansion program, Hemosol's scientific team has developed methods to produce hemoglobin from cultured cells, as well as a promising cell therapy that could be used to augment current cancer treatment. The Company is also active in the

June 20, 2002
[Hemosol Receives K Approval](#)

June 07, 2002
[Hemosol Announces HEMOLINK Clinical](#)

June 05, 2002
[Hemosol Addresses Therapeutics as a P Drug Class](#)

April 30, 2002
[Hemosol to Hold An Special Meeting of May 2, 2002](#)

April 25, 2002
[Hemosol Announces 2002 Financial Resu](#)

April 15, 2002
[Hemosol Announces First Quarter 2002](#)

April 11, 2002
[Hemosol Files Final Public Offering And Credit Facility](#)

March 28, 2002
[Hemosol Enters Agr Increase Bought De Million](#)

March 27, 2002
[Hemosol Enters Agr \\$15 Million Bought](#)

March 26, 2002
[Hemosol Receives C U.S. FDA to Begin S HEMOLINK as a Tre Chemotherapy-Indu](#)

March 20, 2002
[Hemosol Announces Will Not be Cleared in Canada This Year](#)

February 14, 2002
[Hemosol Announces Financial Results](#)

February 07, 2002
[Hemosol Announces Fourth Quarter and Financial Results](#)

January 31, 2002
[Hemosol Commenc Hemolink™ Study i](#)

January 29, 2002
[Hemosol Oxygen Th Research Shows Pr](#)

identification and characterization of new factors controlling blood cell growth.

About Hemosol Inc. Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product HEMOLINK™ [hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company's pipeline includes several new product candidates designed to address major markets with unmet medical needs including transfusion medicine, tissue reperfusion, oncology and infectious disease indications based upon its protein bioconjugation and cell expansion technologies.

For more information visit Hemosol's website at www.hemosol.com.

Hemosol Inc.'s common shares are listed on The NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".

HEMOLINK™ and HepSelect™ are trademarks of Hemosol Inc.

Certain statements concerning Hemosol's future prospects are "forward-looking statements" under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol's ability to obtain regulatory approvals for its products; Hemosol's ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for

Notice: The Company information contained on this website is updated from time to time but may not be current at time of view. Information may also contain forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially, including uncertainties associated with the conduct of clinical trials. It should be noted that Hemosol's products are currently under development and that regulatory approval for the sale of its products has not been sought or attained.

© 2002 Hemosol Inc.

[Prevention of Tissue Injury](#)

[December 10, 2001
Hemolink Delivers Significant
Amount of Oxygen
Results Presented at
Society of Hematology
Annual Meeting](#)

[November 21, 2001
Hemosol Resumes
Program for Hemolink](#)

[October 31, 2001
BLOOD USAGE ISSUES
ALTERNATIVES AD
NATIONAL BLOOD
COUNCIL \(NBSC\) MEETING](#)

[October 19, 2001
Hemosol Announces
Release of Third Quarter
Financial Results and
Call](#)

[October 16, 2001
New Study Suggests
Is Higher Than Reported](#)

[Show All News Releases](#)

See Also:

[Annual Report 2001
Interactive version
PDF \(2.99 MB\)](#)

[Q1 President's Message](#)

[Fact Sheet
PDF \(66 K\)](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEMOSOL INC.

Date: June 20, 2002

By: 

Name: Lee D. Hartwell

Title: Chief Financial Officer and Vice-
President Corporate Development